Kenvue Inc. (NYSE:KVUE) Receives $22.64 Consensus Target Price from Analysts

Kenvue Inc. (NYSE:KVUE) has been assigned an average recommendation of “Hold” from the twelve analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $22.64.

A number of analysts have recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft raised their target price on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Piper Sandler raised their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. JPMorgan Chase & Co. raised their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a report on Tuesday, September 24th. Finally, UBS Group raised their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th.

Hedge Funds Weigh In On Kenvue

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Leo Wealth LLC lifted its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares in the last quarter. Alerus Financial NA lifted its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC raised its position in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the last quarter. Finally, Marathon Capital Management raised its position in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $23.18 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a fifty day moving average price of $22.97 and a two-hundred day moving average price of $21.05. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a market capitalization of $44.44 billion, a P/E ratio of 42.15, a P/E/G ratio of 2.20 and a beta of 1.37.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the company posted $0.31 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. As a group, analysts anticipate that Kenvue will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.